Novel radiosurgical platform to treat a case of uveal melanoma
Source: Ophthalmology Times, April 2025
Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)
A relatively new technology, the ZAP-X® system (Zap Surgical Systems Inc., San Carlos, CA), described by investigators as a “dedicated self-contained and self-shielded surgical robot for performing stereotactic surgery (SRS) of the brain, head, and neck,” was used to treat a patient with uveal melanoma.
The investigative team, led by Stephan Kinzl, MD, explained that “SRS is a recognized procedure for treating benign tumors including vestibular schwannoma, meningioma, pituitary adenoma, neuroma of other cranial nerves, and glomus-jugular tumors, and malignant tumors like brain metastasis, glioblastoma recurrence, and chondrosarcoma and for treating trigeminal neuralgia and arteriovenous malformations. Kinzl is from the Department of Ophthalmology, Stadtspital Zurich, Zurich. He and his colleagues reported their experience with the Zap-X system in Cureus.1